Author: Zeng, Qing-Lei; Yu, Zu-Jiang; Gou, Jian-Jun; Li, Guang-Ming; Ma, Shu-Huan; Zhang, Guo-Fan; Xu, Jiang-Hai; Lin, Wan-Bao; Cui, Guang-Lin; Zhang, Min-Min; Li, Cheng; Wang, Ze-Shuai; Zhang, Zhi-Hao; Liu, Zhang-Suo
Title: Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients Cord-id: x4zuv4jo Document date: 2020_4_29
ID: x4zuv4jo
Snippet: Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died
Document: Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date